Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sildenafil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A known ✓ | O76074 | 20/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 2/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.82 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.82 |
| ▸ | PDE2A | O00408 | 1/20 | 0.82 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.82 |
| ▸ | PDE6D | O43924 | 1/20 | 0.82 |
| ▸ | PDE8A | O60658 | 1/20 | 0.82 |
| ▸ | PDE9A | O76083 | 1/20 | 0.82 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.82 |
| ▸ | HTR1A | P08908 | 1/20 | 0.82 |
| ▸ | PDE6A | P16499 | 1/20 | 0.82 |
| ▸ | PDE6G | P18545 | 1/20 | 0.82 |
| ▸ | PDE4A | P27815 | 1/20 | 0.82 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.82 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.82 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.82 |
| ▸ | PDE6B | P35913 | 1/20 | 0.82 |
| ▸ | PDE6C | P51160 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sildenafil SCHEMBL6509338 | 1.00 | PDE5A (1.00) | PDE5AABCC4PDE3BPDE3APDE2A | |
| Sildenafil SCHEMBL405882 | 1.00 | PDE5A (1.00) | PDE5AABCC4PDE3BPDE3APDE2A | |
| Sildenafil SCHEMBL29424508 | 1.00 | PDE5A (1.00) | PDE5AABCC4PDE3BPDE3APDE2A | |
| Sildenafil SCHEMBL405881 | 1.00 | PDE5A (1.00) | PDE5AABCC4PDE3BPDE3APDE2A | |
| Sildenafil SCHEMBL28791531 | 0.99 | PDE5A (0.99) | PDE5AABCC4PDE3BPDE3APDE2A | |
| Sildenafil SCHEMBL27980438 | 0.99 | PDE5A (0.99) | PDE5AABCC4PDE3BPDE3APDE2A | |
| Sildenafil SCHEMBL6685385 | 0.99 | PDE5A (0.99) | PDE5AABCC4PDE3BPDE3APDE2A | |
| Sildenafil SCHEMBL19410963 | 0.99 | PDE5A (0.99) | PDE5AABCC4PDE3BPDE3APDE2A | |
| Sildenafil SCHEMBL17101160 | 0.99 | PDE5A (0.97) | PDE5AABCC4PDE3BPDE3APDE2A | |
| Sildenafil SCHEMBL7374712 | 0.98 | PDE5A (0.96) | PDE5AABCC4PDE3BPDE3APDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 17817 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122055146-A | Novel use of PDE5 inhibitors in combination to promote neurite outgrowth | 未来新药股份有限公司 | 2026-05-15 | — | — | CN | claimed |
| US-20250387343-A1 | Nanoparticle Compositions and Methods for Synthesis Thereof | ICEUTICA PTY LTD (AU) | 2025-12-25 | — | — | US | claimed |
| EP-3731870-B1 | LIQUID ORAL FORMULATIONS FOR PDE V INHIBITORS | LIQMEDS LTD (GB) | 2025-11-12 | — | — | EP | claimed |
| WO-2025231184-A1 | HYDROGEL COMPOSITIONS FOR VASCULAR ASSOCIATED TREATMENT AND METHODS | ROWAN UNIVERSITY (US) | 2025-11-06 | — | — | WO | claimed |
| WO-2025222280-A1 | STABLE TOPICAL COMPOSITIONS FOR TREATING ATROPHIC VAGINITIS | JASTLABS CORPORATION (CA) | 2025-10-30 | — | — | WO | claimed |
| WO-2025222268-A1 | TOPICAL COMPOSITIONS AND METHODS FOR TREATING ATROPHIC VAGINITIS | JASTLABS CORPORATION (CA) | 2025-10-30 | — | — | WO | claimed |
| US-20250248940-A1 | Biopolymer Formulations for Drug Delivery | 11584022 CANADA INC. (CA) | 2025-08-07 | — | — | US | claimed |
| US-20250241824-A1 | CHILD-PROOF STICK PACK | BAYER HEALTHCARE LLC | 2025-07-31 | — | — | US | claimed |
| US-20250241924-A1 | TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS | STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) | 2025-07-31 | — | — | US | claimed |
| CN-120189513-A | Pharmaceutical composition and application thereof in preparing compound preparation | 北京辰光医药科技有限公司 | 2025-06-24 | — | — | CN | claimed |
| WO-2000053148-A2 | METHODS AND COMPOSITIONS FOR TREATING ERECTILE DYSFUNCTION | MERCK & CO., INC. (US) | 2000-09-14 | — | — | WO | claimed |
| WO-2000050007-A1 | COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF HYDROPHOBIC THERAPEUTIC AGENTS | LIPOCINE, INC. (US) | 2000-08-31 | — | — | WO | claimed |
| WO-2000042992-A2 | COMPOSITIONS AND METHODS FOR MUCOSAL DELIVERY | LAVIPHARM LABORATORIES, INC. (US) | 2000-07-27 | — | — | WO | claimed |
| WO-2000038655-A1 | DOSAGE FORMS COMPRISING POROUS PARTICLES | ALZA CORPORATION (US) | 2000-07-06 | — | — | WO | claimed |
| WO-2000000199-A1 | NASAL DELIVERY OF SILDENAFIL CITRATE | NASTECH PHARMACEUTICAL COMPANY, INC. (US) | 2000-01-06 | — | — | WO | claimed |
| WO-1999066924-A1 | USE OF NITRIC OXIDE SCAVENGERS TO TREAT SIDE EFFECTS CAUSED BY THERAPEUTIC ADMINISTRATION OF SOURCES OF NITRIC OXIDE | MEDINOX, INC. (US) | 1999-12-29 | — | — | WO | claimed |
| WO-1999059584-A1 | COMBINATION OF PHENTOLAMINE AND CYCLIC GMP PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | SCHERING CORPORATION (US) | 1999-11-25 | — | — | WO | claimed |
| WO-1999051252-A1 | COMPOSITIONS COMPRISING L-ARGININE, GINSENG AND GINGKO BILOBA FOR ENHANCING BLOOD CIRCULATION | THE DAILY WELLNESS COMPANY (US) | 1999-10-14 | — | — | WO | claimed |
| WO-1999030697-A2 | COMBINATION EFFECTIVE FOR THE TREATMENT OF IMPOTENCE | PFIZER PRODUCTS INC. (US) | 1999-06-24 | — | — | WO | claimed |
| WO-1999030688-A1 | METHODS OF LYOPHILIZING SOLUTIONS | AUFFRET ANTHONY (GB) | 1999-06-24 | — | — | WO | claimed |